The IPN resistance QTL was independently reported by Moen et al [5] and subsequently the resistance phenotype was partially attributed to a missense variant in the cdh1–1 gene, which encodes a cell surface receptor [7]. This evidence concerns the gene CD177 and bile duct papillary neoplasm.